FivepHusion has announced that a poster of the most recently completed deflexifol clinical trial was presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco.
The company said the FP101A dose-escalation clinical study of deflexifol monotherapy demonstrated that concomitant delivery of 5-fluorouracil (5-FU) and its biomodulator leucovorin via deflexifol is safe and tolerable in solid tumour patients at 5-FU doses up to 40 per cent higher than typically administered by the standard ‘modified de Gramont’ regimen.
Disease control was achieved in 69 per cent of evaluable patients, all of whom were end-stage and typically heavily pre-treated, including with prior 5-FU.
The study’s principal investigator, Associate Professor Daniel Brungs, presented the poster.
“The FP101A trial results were well received by oncologists attending the conference. It is pleasing to have the opportunity to discuss the promising Deflexifol clinical results with colleagues at one of the preeminent international conferences focused on gastrointestinal cancer treatments. There is a desperate need for new therapeutic options for the treatment of colorectal cancer and other GI cancers,” said Associate Professor Brungs.
